SpyGlass Pharma, Inc.
Spyglass Pharma is dedicated to developing innovative, long-term drug delivery solutions for ophthalmic diseases, particularly targeting glaucoma management during cataract surgery. Their pioneering platform aims to provide multi-year therapy through intraocular implants, addressing the unmet need for consistent medication delivery independent of patient adherence.
Industries
Nr. of Employees
small (1-50)
SpyGlass Pharma, Inc.
27061 Aliso Creek Rd, Suite 100, Aliso Viejo, CA 92656
Patents
Products
IOL-mounted sustained-release intraocular drug delivery platform
A single-piece hydrophobic acrylic intraocular lens combined with two drug-eluting pads that attach to the lens haptics and continuously elute medication into the aqueous humor for multi-year therapy; designed to be implanted during standard cataract surgery.
IOL-mounted sustained-release intraocular drug delivery platform
A single-piece hydrophobic acrylic intraocular lens combined with two drug-eluting pads that attach to the lens haptics and continuously elute medication into the aqueous humor for multi-year therapy; designed to be implanted during standard cataract surgery.
Services
Design and execution of animal studies to assess intraocular pressure effects, ocular safety, systemic exposure, and dose tolerance of intraocular sustained-release implants.
Execution of first-in-human feasibility studies and U.S. FDA-regulated clinical trials to evaluate safety and efficacy of sustained-release intraocular implants in patients with ocular hypertension or open-angle glaucoma.
Research and engineering of an intraocular lens-based delivery platform, including pad formulation, mechanical attachment to IOL haptics, and integration with standard surgical and injection workflows.
Design and execution of animal studies to assess intraocular pressure effects, ocular safety, systemic exposure, and dose tolerance of intraocular sustained-release implants.
Execution of first-in-human feasibility studies and U.S. FDA-regulated clinical trials to evaluate safety and efficacy of sustained-release intraocular implants in patients with ocular hypertension or open-angle glaucoma.
Research and engineering of an intraocular lens-based delivery platform, including pad formulation, mechanical attachment to IOL haptics, and integration with standard surgical and injection workflows.
Expertise Areas
- Intraocular drug delivery
- Drug-device combination development
- Clinical trial management in ophthalmology
- Preclinical ocular pharmacology and safety
Key Technologies
- Controlled-release intraocular drug delivery
- IOL-integrated drug-eluting pads
- Hydrophobic acrylic single-piece intraocular lenses
- Haptic-mounted attachment mechanisms